abstract: Phospholipase C-zeta (PLCz) is a sperm-specific protein believed to cause Ca 2+ oscillations and egg activation during mammalian fertilization. PLCz is very similar to the somatic PLCd1 isoform but is far more potent in mobilizing Ca 2+ in eggs. 
Introduction
Egg activation is the first and most crucial step that initiates embryo development after fertilization (Runft et al., 2002) . Compelling evidence indicates that sperm-specific phospholipase C-zeta (PLCz) represents the sole physiological stimulus for egg activation and subsequent embryonic development during mammalian fertilization Saunders et al., 2002; Kouchi et al., 2004; Knott et al., 2005; Yoon et al., 2008) . Upon sperm -egg fusion, PLCz is delivered from the fertilizing sperm into the egg cytoplasm, triggering the Ca 2+ oscillations that are responsible for causing all the major events of egg activation, such as cortical granule exocytosis to block polyspermy, resumption of second meiotic division and initiation of the first mitotic cell cycle . Sperm-delivered PLCz catalyzes the hydrolysis of its membranebound phospholipid substrate, phosphatidylinositol 4,5-bisphosphate (PIP 2 ), thus generating intracellular Ca 2+ oscillations via the inositol 1,4,5-trisphosphate (InsP 3 ) signaling pathway . The importance of PLCz in mammalian fertilization has been further highlighted by a number of clinical reports that directly link defects or deficiencies in human PLCz with documented cases of male infertility (Yoon et al., 2008; Heytens et al., 2009; Nomikos et al., 2011a; Kashir et al., 2012) . In addition, it has been recently demonstrated that recombinant human PLCz can phenotypically rescue failed activation of mouse eggs caused by dysfunctional PLCz, leading to efficient † These authors contributed equally to this work.
blastocyst formation in a prototype of male factor infertility (Nomikos et al., 2013) . PLCz is the smallest with the most elementary domain organization among all identified mammalian PLC isoforms. PLCz exhibits a typical PLC domain structure consisting of four tandem EF hand domains at the N-terminus, the characteristic X and Y catalytic domains in the center followed by a single C-terminal C2 domain, all of which are common to the other PLC isoforms (b, g, d, 1 and h; Nomikos et al., 2012; Swann and Lai, 2013) . The XY catalytic domain is the most highly conserved region of PLC compared with other regulatory domains. The PLCz XY domain shows a 60% sequence similarity to that of all PLC isoforms (Saunders et al., 2007) . Mutagenesis of conserved active site residues within the catalytic domain of PLCz leads to a total loss of enzymatic function and thus Ca 2+ oscillation-inducing ability of PLCz Swann and Lai, 2013) . Interestingly, mutations within the catalytic domain of PLCz have been associated with loss of function in human sperm from an infertile male (Heytens et al., 2009; Kashir et al., 2011; Nomikos et al., 2011a Nomikos et al., , 2013 . The X and Y catalytic domains are separated by an unstructured linker region. In PLCz, a part of this linker region that is proximal to the Y domain contains a distinctive cluster of basic amino acid residues not found in the homologous region of any of the other PLC isoforms. In these somatic PLC isoforms, it has been demonstrated that the XY-linker confers potent inhibition of enzymatic activity, suggesting that this region may play a common auto-regulatory role (Hicks et al., 2008; Gresset et al., 2010) . In contrast, the XY-linker of PLCz does not confer enzymatic autoinhibition, but conversely appears to be required for maximal enzymatic activity (Nomikos et al., 2011b) . Sequence alignment analysis revealed that PLCz has the greatest homology with PLCd1 (47% similarity, 33% identity; Saunders et al., 2002 Saunders et al., , 2007 Nomikos et al., 2012 ). However, a major difference which distinguishes PLCz from PLCd1 and other somatic PLC isoforms is the absence of a PH domain at the N-terminus (Fig. 1) . PH domains are well-defined structural modules of 120 amino acid residues that mediate the membrane binding of somatic PLC isoforms (Lomasney et al., 1996; Bae et al., 1998; Falasca et al., 1998; Singh and Murray, 2003) . PLCd1 binds strongly to biological membranes through its PH domain, which displays high binding affinity and specificity to the membrane-bound PLC substrate, PIP 2 (Lomasney et al., 1996) . The notable lack of a PH domain makes it unclear how the sperm PLCz would interact with membranes. We have recently suggested that PLCz may interact with its membranebound substrate via the electrostatic interaction of a cluster of positively charged residues that are present between the X and Y catalytic domains (i.e. the XY-linker region) with the negatively charged PIP 2 (Nomikos et al., 2007 (Nomikos et al., , 2011c . Interestingly, we have also demonstrated that whilst PLCd1 targets PIP 2 in the plasma membrane, PLCz appears to target intracellular PIP 2 stores on distinct vesicular structures within the egg cytoplasm (Yu et al., 2012 PLCz/PLCd1 hybrids identify domain signaling roles
Materials and Methods

Cloning of PLCz/PLCd1 chimeric constructs
The PHd1/PLCz-luc construct was cloned into pCR3 vector by using a three step cloning strategy. The PH domain of rat PLCd1(1-129aa) (GenBank TM accession number M20637) was amplified by PCR using Phusion polymerase (Finnzymes) and appropriate primers in order to incorporate a 5 ′ -KpnI site and a 3 ′ -EcoRI site and the product was cloned into the pCR3 vector. Fulllength mouse PLCz (1-647aa) was then amplified from the original cDNA clone (GenBank TM accession number AF435950) with the appropriate primers to incorporate a 5 ′ -EcoRI site and a 3 ′ -NotI site in which the stop codon had been removed, and the product was cloned into the pCR3-PLCd1 1 -129 plasmid. Finally, the firefly luciferase open reading frame was amplified from pGL2 (Promega) with primers incorporating NotI sites and the product was cloned into the NotI site of the pCR3-PLCd1 1 -129 -PLCz 1 -647 plasmid, thus creating pCR3-PLCd1 1 -129 -PLCz 1 -647 -luciferase (PHd1/PLCz-luc; Fig. 1 ). The EFd1/PLCz-luc and PLCz/C2d1-luc chimeras were cloned into the pCR3 vector by using a three step overlapping PCR reaction approach. First, primers were designed to amplify the regions of interest from mouse PLCz and rat PLCd1 and also to contain an overlapping sequence to link both inserts at a later stage. For EFd1/PLCz-luc, the EF hands of PLCd1 (135-258aa) were amplified containing a 3 ′ -end sequence corresponding to the 5 ′ -end of DEF/PLCz (147-647aa), while DEF/PLCz was amplified containing the 5 ′ -end sequence designed to overlap the 3 ′ -end sequence of the amplified EF hands (Fig. 1) .
For PLCz/C2d1-luc, the C2 domain of PLCd1 (614 -756aa) was amplified to contain the 5 ′ -end sequence of the 3 ′ -end sequence of PLCz/DC2 (1-503aa); and PLCz/DC2 sequence was amplified containing the 3 ′ -end sequence designed to overlap the 5 ′ -end sequence of the amplified C2 domain. Once these constructs had been amplified, an overlapping reaction was carried out in order to link the corresponding inserts and produce the EFd1/PLCz and PLCz/C2d1 (Fig. 1 ). These were cloned into pCRXL TOPO and then subcloned into the pCR3 vector. Luciferase was then cloned into pCR3-EFd1/PLCz and pCR3-PLCz/C2d1 plasmids in the same fashion as described above, resulting in the same short linker sequence CAAA between the PLCz and luciferase. This strategy enabled creation of pCR3-PLCd1 135 -258 -PLCz 147 -647 -luciferase (EFd1/PLCz-luc) and pCR3-PLCz 1-503 -PLCd1 614-756 -luciferase (PLCz/C2d1).
The PLCz/XYd1-luc and PLCz/XYlinkd1-luc constructs were cloned into pCR3 vector by using a four step cloning strategy. For PLCz/XYd1-luc, PLCz(1 -150aa), was amplified by PCR with primers to incorporate a 5 ′ -KpnI site and a 3 ′ -EcoRI site and then cloned into the pCR3 vector. The XY domain of PLCd1(285-631aa) was then amplified from the original cDNA clone with primers to incorporate a 5 ′ -EcoRI site and a 3 ′ -EcoRV site and cloned into the pCR3-PLCz (Fig. 1) . The same strategy was followed for the PLCz/ XYlinkd1-luc construct but the corresponding constructs that sequentially amplified and cloned using the same restriction enzymes were PLCz(1-307aa), PLCd1(441-490aa) and PLCz(386-647aa), respectively, thus creating PLCz/XYlinkd1. The DPH/PLCd1-luc construct was cloned into pCR3 vector by using a two-step cloning strategy. PLCd1(135-756aa) was amplified using the appropriate primers to incorporate a 5 ′ -EcoRV site and a 3 ′ -NotI site in which the stop codon had been removed and cloned into the pCR3 vector. Then luciferase was amplified as above and the product was cloned into the NotI site of the pCR3-PLCd1 135 -756 plasmid to generate DPH/ PLCd1 (Fig. 1 ). All the above chimeric constructs, except without the C-terminus luciferase portion, were amplified from the pCR3 vector with the appropriate primers to incorporate a 5 ′ -SalI site and a 3 ′ -NotI site and the product was cloned into the pETMM60 vector to enable bacterial protein expression. Each of the above expression vector constructs was confirmed by dideoxynucleotide sequencing (Prism Big Dye kit; ABI Prismw 3100 Genetic Analyzer, Applied Biosystems, Warrington, UK).
cRNA synthesis
Following linearization of wild-type and chimeric PLC plasmids, cRNA was synthesized using the mMessage Machine T7 kit (Ambion) and then was polyadenylated using the poly(A) tailing kit (Ambion), as per the manufacturer's instructions.
Preparation and handling of gametes
Experiments were carried out with mouse eggs in Hepes-buffered media (H-KSOM) as previously described (Nomikos et al., 2005 (Nomikos et al., , 2011b . All compounds were from Sigma unless stated otherwise. Female mice were superovulated and eggs were collected 13.5 -14.5 h after injection of human chorionic gonadotrophin (hCG) and maintained in droplets of M2 media (Sigma) or H-KSOM under mineral oil at 378C. Microinjection of the eggs was carried out 14.5 -15.5 h after the hormone injection. Eggs were obtained from mice using standard procedures that have been approved by the UK Home Office.
Microinjection and measurement of intracellular Ca 21 and luciferase expression
Mouse eggs were washed in M2 media and microinjected with cRNA diluted in injection buffer (120 mM KCl, 20 mM Hepes, pH 7.4). The volume injected was estimated from the diameter of cytoplasmic displacement caused by the bolus injection. All injections were 3 -5% of the egg volume. Eggs were microinjected with the appropriate cRNA, mixed with an equal volume of 1 mM Oregon Green BAPTA dextran (Molecular Probes) in the injection buffer. Eggs were then maintained in H-KSOM with 100 mM luciferin and imaged on a Nikon TE2000 or Zeiss Axiovert 100 microscope equipped with a cooled intensified CCD camera (Photek Ltd, UK). Ca 2+ was monitored in these eggs for 4 h after injection by measuring the fluorescence of Oregon Green BAPTA dextran (OGBD) with low level excitation light from a halogen lamp. The OGBD fluorescence was collected intermittently (10 s every 20 s), and the light measured in the intervals between fluorescence excitation taken as the luminescence due to luciferase. Hence we could monitor both cytoplasmic Ca 2+ concentration changes and recombinant luciferase protein luminescence over the same time period in eggs as they expressed each of the various PLC-luc constructs. The fluorescence signals were typically 100 times greater than the luminescence signals. Ca 2+ measurements for an egg were further analyzed only if the same egg was also luminescent during the experiment. The luminescence from eggs was converted into an amount of luciferase using a standard calibration plot that was generated by placing eggs in a luminometer that had been previously calibrated by microinjection with known amounts of luciferase protein (Sigma) (Nomikos et al., 2005; 2011b, c; Swann et al., 2009 ).
Protein expression and purification
For bacterial expression of NusA-6His-tagged PLC chimera fusion proteins, Escherichia coli [Rosetta (DE3) cells, Novagen] was transformed with the appropriate pETMM60-PLC plasmid construct and cultured at 378C until the A 600 reached 0.6, and then protein expression was induced for 18 h at 168C with 0.1 mM isopropyl b-D-thiogalactopyranoside (Promega). Cells were harvested by centrifugation at 6000g for 10 min, resuspended in phosphate-buffered saline (PBS: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 . 7H 2 O, 1.4 mM KH 2 PO 4 , pH 7.4) containing 2 mM dithiothreitol, and protease inhibitor mixture (Roche Applied Science), and then sonicated four times for 15 s on ice. After 15 min of centrifugation at 15 000g, 48C, soluble 6xHis-tagged protein was purified by affinity chromatography using Ni-NTA resin (Qiagen) and eluted with 250 mM imidazole. Eluted proteins were dialyzed overnight (Pierce; SnakeSkin 10 000 molecular weight cutoff) at 48C against 4 l of PBS, and concentrated with centrifugal concentrators (Sartorius; 10 000 MWCO).
Assay of PLC activity
PIP 2 hydrolytic activity of recombinant wild-type and chimeric PLC proteins was assayed as described elsewhere (Nomikos et al., 2005; 2011b, c) . The final volume of the assay mixture was 50 ml containing 100 mM NaCl, 0.4% sodium cholate (w/v), 2 mM CaCl 2 , 4 mM EGTA, 20 mg of bovine serum albumin, 5 mM 2-mercaptoethanol and 20 mM Tris-HCl buffer, pH 6.8. The final concentration of PIP 2 in the reaction mixture was 220 mM, containing 0.05 mCi of [ 3 H]PIP 2 . The assay conditions were optimized for linearity, requiring a 10-min incubation of 20 pmol of PLC protein sample at 258C. Reactions were stopped by addition of 0.25 ml of chloroform/methanol/concentrated HCl (100:100:0.6 v/v) followed by 0.075 ml of concentrated HCl. The mixture was vortexed and centrifuged at 2000g for 2 min, and then 0.2 ml of the upper aqueous phase was removed and added to 10 ml of Optiphase 'Hisafe 3' scintillation mixture (Wallac), and the radioactivity was determined by liquid scintillation spectrofluorimetry (Packard Tri-Carb 2100TR). In assays to determine dependence on PIP 2 concentration, 0.05 mCi of [ 3 H]PIP 2 was admixed with cold PIP 2 to
give the appropriate final concentration. In assays examining the Ca 2+ sensitivity, Ca 2+ buffers were prepared by EGTA/CaCl 2 admixture, as previously described (Nomikos et al., 2005) .
Liposome preparation and binding assay
Unilamellar liposomes were prepared as previously described (Nomikos et al., 2011c) by the extrusion method using a laboratory extruder (LiposoFast-Pneumatic, Avestin Inc., Ottawa, ON, Canada) with lipids purchased from Avanti Polar Lipids Inc. (Alabaster, AL). In a typical experiment requiring a 2 ml dispersion of liposomes, 0.038 mmol (1910 -3 M) of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 0.019 mmol (9.5 × 10 -3 M) of cholesterol (molar ratio DPPC:CHOL 2:1), 0.0095 mmol (4.8 × 10 -3 M) 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE) (molar ratio DPPC:DMPE 4:1) and 1 or 5% of total lipids [16:50:38] phosphatidylcholine/phosphatidylinositol (PCPI) were dissolved in chloroform/ methanol (2:1, v/v) for the formation of lipid films. The film was hydrated with 2 ml of PBS and the resultant suspension was extruded through two-stacked polycarbonate filters of 100 nm pore size. Twenty-five cycles of extrusion were applied at 508C. For the control experiments, unilamellar liposomes without PCPI were prepared in an analogous manner. Dynamic light scattering (DLS) was employed to determine the size of the liposomes, which used a light scattering apparatus (AXIOS-150/EX, Triton Hellas) with a 30 mW laser source and an Avalanche photodiode detector set at a 90 0 angle. DLS measurements of the extruded lipid preparation showed a narrow monomodal size distribution with average liposome diameter of 100 nm and a polydispersity index of 0.20 -0.25. For protein binding studies the liposomes (100 mg of 4:2:1 DMPC:CHOL:DMPE) containing 0 -1% PI(4,5)P 2 or 5% PI(3)P were incubated with 1 mg of recombinant protein for 30 min at RT and centrifuged for 6 h at 48C. The supernatant and pellet were then analyzed by SDS -PAGE and Coomassie Blue staining as previously described (Nomikos et al., 2011c) .
SDS -PAGE and western blotting
Recombinant proteins were separated by SDS -PAGE as previously described (Nomikos et al., 2011b,c) . Separated proteins were transferred onto polyvinylidene difluoride membrane (Immobilon-P; Millipore) using a semi-dry transfer system (Trans-Blot SD; Bio-Rad) in buffer (48 mM Tris, 39 mM glycine, 0.0375% SDS) at 22 V for 4 h (Mackrill et al., 1997) . The membrane incubated overnight at 48C in Tris-buffered saline, 0.1% Tween 20 (TBS-T) containing 5% non-fat milk powder, and probed with anti-NusA monoclonal antibody (1:25 000 dilution). Detection of horseradish peroxidasecoupled secondary antibody was achieved using enhanced chemiluminescence detection (ECL; Amersham Biosciences).
Mathematical modeling of Ca 21 dynamics
The mathematical model (see Appendix for details) consists of a system of three differential equations, which account for time-dependent fluctuations in the inter- (Atri et al., 1993; Politi et al., 2006) . Numerical simulations were run in parallel on code written in C++ and MATLAB software (Mathworks).
Results
Ca 21 oscillation-inducing activity of PLCz/ PLCd1 chimeras expressed in unfertilized mouse eggs
To investigate the regulatory role of the distinct PLCz domains on the in vivo Ca 2+ oscillation-inducing activity and the in vitro biochemical properties of this enzyme, a series of chimeric constructs of PLCz with various PLCd1 domains were designed. To generate these chimeric plasmids, PLCz served as the template and then discrete domains of PLCz were replaced by the corresponding domain of PLCd1 (Fig. 1) . Five chimeric Table I ).
constructs were generated; PLCz containing either the N-terminal PH domain (PHd1/PLCz), the EF hands domain (EFd1/PLCz), the XY catalytic domain (PLCz/XYd1), the XY-linker (PLCz/XYlinkd1) or the C2 domain (PLCz/C2d1) of PLCd1 (Fig. 1) . In addition to the wild-type PLCz and PLCd1 constructs that served as controls for our studies, a further control construct generated was PLCd1 lacking the PH domain (DPH/PLCd1). This construct provides a domain organization precisely matching with PLCz. In order to test the ability of these eight constructs to trigger Ca 2+ oscillations and to verify their expression upon microinjection of the corresponding cRNA into mouse eggs, each construct was tagged at the C-terminus with luciferase. This strategy enables realtime monitoring of relative recombinant protein expression in live cells by luminescence quantification (Swann et al., 2009; Nomikos et al., 2013) . Figure 2 and Table I Table I ). Microinjection of cRNA corresponding to wild-type PLCd1 induced very-low-frequency Ca 2+ oscillations ( 2 spikes/2 h) that commenced only after PLCd1 protein expression to 20.3 cps was achieved. This is consistent with our previous observations of injected cRNA encoding wild-type PLCd1 into mouse eggs (Nomikos et al., 2011b) . These data indicate that substitution of the XY catalytic domain, XY-linker or C2 domain of PLCz with the corresponding domain of PLCd1 completely abolishes Ca 2+ oscillation-inducing activity in mouse eggs. In addition, deletion of the PH domain alone from PLCd1 to give it a PLCz-like structural organization does not confer the truncated PLCd1 isoform with oscillogenic activity.
Expression and enzymatic characterization of PLCz chimeras
PLCd1, DPH/PLCd1 and all the chimeric PLCz constructs were subcloned into the pETMM60 vector and purified as NusA-6His-tagged fusion proteins. We have recently demonstrated that NusA is the most efficient fusion partner for PLCz, significantly increasing the expression of soluble PLCz protein in a bacterial host, E. coli, as well as enhancing the enzymatic stability of the purified protein (Nomikos et al., 2013) . As described in 'Experimental Procedures', optimal protein production for all NusA-tagged PLCz/PLCd1 constructs required induction of protein expression with 0.1 mM IPTG for 18 h at 168C. Following induced expression in E. coli and isolation by affinity chromatography, the purified PLC protein samples were characterized. Figure 3 shows wild-type NusA-tagged PLCz, PLCd1, DPH/PLCd1 and the five PLCz chimeras analyzed by SDS-PAGE (left panels) and immunoblot detection with an anti-NusA monoclonal antibody (right panels). The major protein band with mobility corresponding to the predicted molecular mass for each construct was present for all the samples and these major bands were also confirmed by the anti-NusA antibody after immunoblot analysis (Fig. 3) . For some constructs, fainter low molecular weight bands could be observed, which were also detected by the antiNusA antibody, and are probably the result of protease degradation occurring during the stages of protein isolation. The specific PIP 2 hydrolytic enzyme activity for each recombinant protein was determined using the standard in vitro spike number in 2 h) and luciferase luminescence levels (peak luminescence; luminescence at first spike) are summarized for mouse eggs microinjected with each of the PLC-luciferase constructs; PLCz, PHd1/PLCz, EFd1/PLCz, PLCz/XYlinkd1, PLCz/XYd1, PLCz/C2d1, PLCd1 and DPH/PLCd1 (see Figs 1 and 2) . The data are expressed to two significant figures, with means + SEM.
PLCz/PLCd1 hybrids identify domain signaling roles
To compare the enzyme kinetics of wild-type PLCz and the PLCz chimeras, as well as of wild-type PLCd1 and DPH/PLCd1 recombinant proteins, the Michaelis-Menten constant, K m for the PIP 2 substrate was calculated (Table II) . The K m value obtained for wild-type PLCz (100 mM), PHd1/PLCz (96 mM), EFd1/PLCz (120 mM) and PLCz/C2d1 (106 mM) chimeras were nearly identical. In contrast, the K m for PLCz/XYlinkd1 and PLCz/XYd1 was 36-fold (3602 mM) and 24-fold (2431 mM) higher than that of wild-type PLCz, respectively (Table II) . These results indicate that replacement of the entire XY catalytic domain or the short XY-linker of PLCz with that of PLCd1 dramatically reduces the in vitro affinity of PLCz for PIP 2 . In addition, the K m for DPH/PLCd1 protein (746 mM) was 10-fold higher than that of wild-type PLCd1 (76 mM), indicating that absence of the N-terminal PH domain reduces the in vitro affinity of PLCd1 for its substrate, PIP 2 .
To investigate the effect of these domain replacements on the Ca 
Binding of PLCz chimeras to PIP 2 and PI(3)P
To examine the binding properties of wild-type PLCz and chimeras to PIP 2 and PI(3)P, we employed a liposome binding assay. For this study, we made unilamellar liposomes composed of PC:CHOL:PE (4:2:1) with incorporation of either 0, 1% PIP 2 or 5% PI(3)P. In order to diminish any non-specific protein binding to highly charged lipids, the liposome binding assays were performed in the presence of a near-physiological concentration of MgCl 2 (0.5 mM). For the binding assay, wild-type PLCd1 and PLCz provided the positive controls, while the NusA moiety was the negative control. NusA did not exhibit any specific liposome binding in the absence or presence of PIP 2 and PI(3)P, whereas PLCz displayed robust binding only to liposomes containing either 1% PIP 2 or 5% PI(3)P (Fig. 6 ). As expected, PLCd1 bound strongly to liposomes containing 1% PIP 2 and remained in the supernatant in the absence of PIP 2 or in the presence of PI(3)P, while deletion of its PH domain led to loss of the binding to liposomes containing 1% PIP 2 . The binding properties of PHd1/PLCz and EFd1/PLCz chimeras were very similar to wild-type PLCz, with binding strongly only to liposomes containing either 1% PIP 2 or 5% PI(3)P. For PLCz/XYlinkd1, the majority ( 90%) of this protein was detected in the supernatant of liposomes containing 0 or 1% PIP 2 , while showing strong binding to liposomes containing 5% PI(3)P (Fig. 6) . Interestingly, the PLCz/XYd1 chimera similar to PLCz/XYlinkd1, did not bind to liposomes containing 0 or 1% PIP 2 but its binding to liposomes containing PI(3)P was much reduced ( 40%). Finally, PLCz/C2d1 did not bind to liposomes containing 0 or 5% PI(3)P, while showing a much reduced binding level ( 25%) to liposomes containing 1% PIP 2 . These data suggest that the XY-linker may provide the major contribution to the physiological interaction of PLCz with PIP 2, while interaction of PLCz with PI(3)P in liposomes requires the C2 domain. ]PIP 2 cleavage assay, n ¼ 3 + SEM, using three different preparations of recombinant protein and with each experiment performed in duplicate. In control experiments with NusA protein alone, there was no specific PIP 2 hydrolysis activity observed (data not shown).
and Figs 2 and 5 confirm the well-described link between levels of the various PLC constructs, InsP 3 expression and the cytosolic Ca 2+ handling apparatus in mammalian eggs. A schematic representation of the basic model beginning with InsP 3 production due to Ca 2+ -dependent hydrolysis of PIP 2 by a PLC isoform, to the InsP 3 -mediated Ca 2+ release from the endoplasmic reticulum is illustrated in Fig. 7a . Individual steps have been incorporated in the modeling scheme outlined in the Appendix (Equations 1-3). The aim is to establish a quantifiable relationship between the experimentally measured parameters describing InsP 3 production and the observed oscillatory Ca 2+ frequency. Simulations for the four chimeras that induce oscillatory activity in Fig. 2 are presented in Fig. 7b , with frequencies closely matching the values calculated in Table I . This was achieved purely by assigning the corresponding Ca 2+ activation constants (the EC 50 ) from NusA-6His-tagged, wild-type PLCz, PLCd1, DPH/PLCd1 and PLCz/ PLCd1 chimeric fusion proteins; PHd1/PLCz, EFd1/PLCz, PLCz/ XYlinkd1, PLCz/XYd1 and PLCz/C2d1. For these assays n ¼ 2 + SEM, using three different batches of recombinant proteins and with each experiment performed in duplicate. Color used for each construct matches the corresponding construct in Fig. 4 .
PLCz/PLCd1 hybrids identify domain signaling roles of oscillatory was variable. Notably, PLCd1 required 40-fold higher levels of expression to initiate low-frequency oscillations. In order to establish a generalized theoretical prediction, we simulated egg Ca 2+ oscillations for a broad range of Ca 2+ sensitivities (EC 50S ) and PLC expression values. The resulting response plots are presented in Fig. 7c and provide a global view of the Ca 2+ dynamics. These results support the experimental observation that an increased EC 50 is associated with lower oscillatory frequency and a delayed onset of Ca 2+ oscillations. Note that the onset of PLCd1-mediated oscillatory activity is subject to a relatively sharp threshold and associated with a prolonged steady state of low-frequency oscillations.
Most previously developed mathematical models of egg fertilization have focused on specific aspects of the process, such as modes of cell activation and intracellular wave formation (Atri et al., 1993) , the relation of Ca 2+ dynamics and various biochemical pathways, e.g. involving growth factors or calmodulin-dependent kinase II activation (Diaz et al., 2005; Dupont et al., 2010) , and modeling of InsP 3 receptors as multi-state processes or non-uniformly distributed units (Ullah et al., 2007; Williams et al., 2008) . In this study, we have maintained a minimal approach since our overall aim was to elucidate causal links between PLC-mediated InsP 3 generation and egg Ca 2+ oscillations. This approach was, nevertheless, able to closely replicate the experimental findings for the onset and frequency of Ca 2+ oscillations during fertilization. The activation contour presented in Fig. 7c reveals an apparent resonance at low EC 50 values, which is evident as a prolonged hump in the plot. This band of heightened activity may account for the apparent increased sensitivity of the PHd1/ PLCz chimera observed experimentally. Our modeling approach assumed a purely concentration-dependent InsP 3 decay. However, InsP 3 degradation occurs via a phosphorylation 
Discussion
Numerous studies support the notion that sperm PLCz is the sole physiological agent responsible for mammalian oocyte activation, by initiating Ca 2+ release from intracellular stores via the activation of the IP 3 / receptor signaling pathway (Ito et al., 2011; Nomikos et al., 2012; Swann and Lai, 2013) . Sperm-specific PLCz is the smallest known PLC, with the simplest domain organization of all PLC isoforms identified to date. Thus, PLCz could be considered a prototypic mammalian PLC isoform, which would also be consistent with the pivotal physiological role that this gamete-derived PLCz is proposed to play in the first steps of mammalian fertilization. Notably, our recent studies suggest that sperm PLCz has a unique regulatory mechanism that is highly distinctive from the regulatory mechanism that operates in the other mammalian somatic cell PLC isoforms (Phillips et al., 2011; Nomikos et al., 2011b; Yu et al., 2012) . PLCz shares the greatest homology with the PLCd1 isoform, but it lacks the PH domain present at the N-terminus of PLCd1 (Fig. 1) . The PH domain is essential for the interaction of PLCd1 with its phospholipid substrate PIP 2 in the plasma membrane. We find that attachment of the PH domain of PLCd1 to the N-terminus of PLCz (PHd1/PLCz) does not alter its in vitro biochemical properties and consequently its ability to trigger Ca 2+ oscillations in unfertilized mouse eggs (Figs 2 and 4, Tables I and II) . This observation suggests that there may be a unique targeting mechanism of PLCz involving determinants other than a PH domain. This may via a potential interaction with either another membrane phospholipid or an eggspecific protein, because even PH domain addition does not localize PHd1/PLCz to the plasma membrane PIP 2 but instead it targets distinct vesicular structures inside the egg cortex, as we had previously observed for the wild-type PLCz (Yu et al., 2012) . PI(3)P might represent a potential physiological ligand for PLCz since previous experimental evidence suggested that the C2 domain of PLCz binds in vitro with significant affinity to PI(3)P and with lower affinity to PI(5)P (Kouchi et al., 2005; Nomikos et al., 2011c) . PI(3)P is a phosphatidylinositol 3-kinase product whose localization is restricted to the limiting membranes of early endosomes and to the internal vesicles of multivesicular bodies (Gillooly et al., 2003) . PI(3)P helps to recruit a range of proteins, many of which are involved in protein trafficking, to these membranes. To further investigate whether full-length PLCz binds PI(3)P, and to determine which domain(s) mediates this interaction and the interaction with the substrate PIP 2 , we employed a liposome binding assay (Fig. 6) . Our current observations suggest that PLCz binds strongly to liposomes containing PIP 2 and PI(3)P and that the EF hand domains of PLCz are not involved in these interactions (Fig. 7a) .
We have previously proposed that the EF hand domains play a vital role in the Ca 2+ sensitivity of PLCz activity, because deletion of both EF hands dramatically changed the EC 50 of PLCz Ca 2+ sensitivity from 82 nM to 30 mM (Nomikos et al., 2005) . In the present study, replacement of the EF hand domains of PLCz with the corresponding domain from PLCd1 (EFd1/PLCz), resulted in a 10-fold decrease in the Ca 2+ sensitivity of PLCz, without affecting its in vivo enzymatic activity or affinity for its substrate, PIP 2 (Fig. 5 , (Swann and Lai, 2013) . Our empirical data and mathematical model together provide a strong indication that the exquisite Ca 2+ sensitivity of PLCz, largely mediated by its EF hand domain, is a major factor in explaining why the sperm-specific PLCz isoform is so much more effective at triggering high-frequency Ca 2+ oscillations than the somatic cell PLCd1 isoform. Replacement of the XY-linker (PLCz/XYlinkd1) or the entire XY domain of PLCz (PLCz/XYd1) with the corresponding region of PLCd1 dramatically decreased the in vitro enzymatic activity and also the affinity of PLCz for PIP 2 (Fig. 4, Table II ). These two chimeras also exhibited an increased EC 50 value for Ca 2+ sensitivity (Fig. 5) , which suggests the involvement of these regions in Ca 2+ regulation of PLCz activity.
Importantly, the replacement of the XY-linker or XY domain of PLCz completely abolished the binding of this enzyme to PIP 2 -containing liposomes (Fig. 6 ). While PLCz/XYlinkd1 bound strongly to PI(3)Pcontaining liposomes, it is interesting that PLCz/XYd1 showed a significantly reduced binding, which suggests that the XY catalytic domain may play a role by contributing to the interaction of PLCz with PI(3)P. The in vitro liposome binding data concurs with the lack of in vivo Ca 2+ oscillation-inducing activity of these two chimeras in mouse eggs. Furthermore, these observations are consistent with previous findings suggesting that the XY-linker plays a central role in the regulation of PLCz enzyme activity and its ability to interact with PIP 2 (Nomikos et al., 2007 (Nomikos et al., , 2011b . PLCz contains a cluster of basic residues in the XY linker region proximal to the Y catalytic domain. These positively charged amino acids in the XY-linker might assist the anchoring PLCz to membranes by enhancing the local PIP 2 concentration adjacent to the XY catalytic domain via electrostatic interactions with the negatively charged PIP 2 . Notably, none of the somatic PLC isozymes possesses such a highly positively charged XY-linker region (Saunders et al., 2007) . In contrast, PLCb, d and 1 contain a highly negatively charged, mostly disordered XY linker region, which has been suggested to mediate auto-inhibition of PLC activity, preventing PIP 2 access to the active site, by a combination of steric exclusion and electrostatic repulsion of negatively charged membranes (Hicks et al., 2008) . Surprisingly, the XY-linker is the most non-conserved region of the PLCz domain sequences determined from different species, except for the presence of positively charged residues. This suggests that the sequence divergence within this region may explain the speciesspecific patterns of Ca 2+ oscillations observed for various mammalian
PLCzs as well as their disparate relative potency when expressed in mouse eggs. Our previous and current investigations suggest that the C2 domain of PLCz is distinct from that of PLCd1 and plays a vital role in PLCz function. Replacement of the C2 domain of PLCz with the corresponding domain of PLCd1 (PLCz/C2d1) completely abolished the Ca 2+ oscillation-inducing activity of PLCz in mouse eggs (Fig. 2, Table I ), although the Ca 2+ sensitivity and affinity of the enzyme for PIP 2 was unaffected (Figs 4 and 5, Table II ). This is in agreement with previous observations where deletion of C2 domain from PLCz led to inability of the C2-truncated protein to trigger Ca 2+ oscillation in mouse eggs, although PIP 2 hydrolytic enzyme activity and Ca 2+ sensitivity was retained (Nomikos et al., 2005) . Despite the fact that most C2 domains bind Ca 2+ , a critical determinant for the activities of their enzymes, there are some C2 domains that do not bind Ca 2+ ions and these bind to phospholipids with relatively low affinity and specificity (Nalefski and Falke, 1996; Hurley and Misra, 2000) . The C2 domain of PLCd1 interacts with the membrane phospholipid, phosphatidylserine (PS), forming a C2-Ca 2+ -PS complex, which enhances the activity of the enzyme (Lomasney et al., 1999) . There is currently no evidence for binding of the C2 domain to PS or other membrane phospholipids. However, if interaction of PLCz with PI(3)P plays a role in targeting of PLCz to the corresponding intracellular PIP 2 -containing vesicle, then the C2 domain may be mediating this interaction, as the PLCz/C2d1 chimera exhibited complete lack of binding to PI(3)P-containing liposomes. This potential intracellular phospholipid-targeting interaction role might explain why the C2 domain is essential for the Ca 2+ oscillation-inducing activity in intact eggs (Nomikos et al., 2005) . Another hypothesis that can be proposed to explain the intracellular targeting of PLCz is that it interacts primarily through the C2 domain with a specific, cytosolic egg protein which is responsible for localizing the sperm PLCz to discrete endomembrane vesicles and not to the plasma membrane (Fig. 7a) . In addition, if the PLCz C2 domain-binding moiety is an egg-specific protein this might explain why PLCz is so effective in eggs but not in other somatic cell types (Phillips et al., 2011) . However, egg-specific PLCz binding protein partners have not yet been identified (Fig. 7) . In future, it will be important to identify the exact intracellular organelle that PLCz targets. In addition, structural determination of the full-length PLCz or its single C2 domain could possibly help to reveal the critical ion and lipid/protein binding sites in the PLCz protein, providing a useful advance in understanding the complex regulatory mechanism of this vital enzyme.
